What are you searching for?

Sign in
Breaking News, Promotions & Moves

GW Pharmaceuticals Appoints CCO

Mr. Darren Cline is an accomplished biopharmaceutical executive with over 25 years of commercial experience

GW Pharmaceuticals plc announced the appointment of Darren Cline as its new U.S. chief commercial officer. 

 
Mr. Cline will lead the Epidiolex U.S. commercial organization and is expected to start on April 22, 2019. He is succeeding Julian Gangolli who, as announced in November 2018, is retiring and will work with Mr. Cline for several weeks as he transitions into the organization.
 
Mr. Cline is an accomplished biopharmaceutical executive with over 25 years of commercial experience and was previously executive vice president, Commercial and a member of the Executive Committee at Seattle Genetics, where he oversaw all marketing, sales, and managed markets functions. 

“We are delighted to have an executive of such high caliber as Darren Cline join our team as the new U.S. Chief Commercial Officer at GW. Darren brings significant commercial experience and a proven track record in execution which will help GW maximize the commercial opportunity of Epidiolex in the U.S. I am confident he will build upon the company’s solid commercial foundation and carry forward our ability to bring this much needed new treatment to patients,” said Justin Gover, GW’s chief executive officer. “I also want to offer our deepest thanks to Julian Gangolli for his expert leadership in building a world-class U.S. commercial organization from scratch and sheparding Epidiolex through a successful launch. We wish him well in his retirement.”

“I am very excited to join GW and to lead such a talented U.S. commercial team,” said Cline. “Epidiolex is an important new treatment that offers hope to many patients with Lennox-Gastaut Syndrome and Dravet syndrome who are in desperate need of new treatments to reduce their seizures. I look forward to continuing to deliver on GW’s mission of bringing transformational medicines to patients and building on the successful commercial organization in place to maximize the Epidiolex opportunity.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters